Safety profiles of sevoflurane in pediatric patients: a real-world pharmacovigilance assessment based on the FAERS database

被引:0
|
作者
Yang, Chuang [1 ]
Deng, Bangjian [1 ]
Wen, Qiang [1 ]
Guo, Pei [2 ]
Liu, Xiang [2 ]
Wang, Chen [2 ]
机构
[1] Chongqing Med Univ, Natl Clin Res Ctr Child Hlth & Disorders, Key Lab Child Dev & Disorders,Childrens Hosp, Dept Pharm,Minist Educ,Chongqing Key Lab Pediat Me, Chongqing, Peoples R China
[2] Sixth Peoples Hosp Chongqing, First Affiliated Hosp, Chongqing Med & Pharmaceut Coll, Dept Clin Pharm,Chongqing Prevent & Treatment Ctr, Chongqing, Peoples R China
关键词
FAERS; adverse events; pediatrics; sevoflurane; pharmacovigilance; GENERAL-ANESTHESIA; PREVENTION; GENDER;
D O I
10.3389/fphar.2025.1548376
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective This study aimed to evaluate the safety profile of sevoflurane in pediatric populations using real-world data.Methods Data were extracted from the Food and Drug Administration Adverse Event Reporting System (FAERS) from the first quarter of 2004 to the third quarter of 2024. We analyzed reports where sevoflurane was the primary suspect in individuals aged 0-18, employing disproportionality analysis to detect adverse events associated with sevoflurane. We also compared the adverse events related to sevoflurane between pediatric and adult populations.Results The FAERS database yielded 21,838,627 adverse event reports for children, with 474 involving sevoflurane as the primary suspect. Descriptive analysis revealed a majority of reports from male patients, primarily reported by physicians. Disproportionality analysis identified significant System Organ Classes (SOC) signals associated with sevoflurane, meeting four detection criteria, including "Cardiac disorders," "Respiratory, thoracic, and mediastinal disorders," and "Vascular disorders." The study also identified previously unreported adverse events, such as "Encephalopathy" and "Hypercapnia." Notable differences in signals were observed between children and adults for "Pulmonary alveolar hemorrhage," "Anaphylactic shock," and "Hypotension."Conclusion Our analysis of the FAERS database identified several significant adverse events associated with sevoflurane in pediatrics, affecting the cardiovascular, respiratory, and nervous systems. Differences in adverse event signals between children and adults were also observed. Furthermore, the new adverse events (such as encephalopathy and hypercapnia) indicated that anesthesiologists should be more vigilant in administering sevoflurane.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Safety evaluation of ILaris: a real-world analysis of adverse events based on the FAERS database
    Yi, Xueliang
    Wu, Shujie
    He, He
    Li, Yingjie
    EXPERT OPINION ON DRUG SAFETY, 2025,
  • [32] Safety assessment of dapagliflozin: Real-world adverse event analysis based on the FAERS database from 2012 to 2023
    Zhou, Zhengxi
    Yao, Xiaotian
    HELIYON, 2024, 10 (12)
  • [33] Safety assessment of tranexamic acid: real-world adverse event analysis from the FAERS database
    Tian, Ningsheng
    Sun, Yuxin
    Liu, Yingying
    Jin, Jie
    Chen, Shuai
    Han, Huawei
    Zhang, Ying
    Li, Zhiwei
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [34] Safety assessment of KRAS (G12C) inhibitors based on the FDA Adverse Event Reporting System (FAERS) database: A real-world pharmacovigilance study
    Chen, Maohua
    Huang, Yaping
    Jiang, Shaojun
    Ke, Chengjie
    LUNG CANCER, 2024, 196
  • [35] Real-world safety of PCSK9 inhibitors: A pharmacovigilance study based on spontaneous reports in FAERS
    Feng, Zhen
    Li, Xiaoye
    Tong, Wai Kei
    He, Qingfeng
    Zhu, Xiao
    Xiang, Xiaoqiang
    Tang, Zhijia
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [36] Safety assessment of Tafamidis: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events
    Li, Yidan
    Sun, Shengzhu
    Wu, Hongyun
    Zhao, Leiyong
    Peng, Wei
    BMC PHARMACOLOGY & TOXICOLOGY, 2024, 25 (01):
  • [37] Real-world pharmacovigilance analysis of galsulfase: a study based on the FDA adverse event reporting system (FAERS) database
    Li, Shangze
    Huang, Runcheng
    Meng, Yuanyuan
    Liu, Yijia
    Qian, Jiao
    Zou, Junjie
    Yang, Jun
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [38] A pharmacovigilance study of adverse event profiles and haemorrhagic safety of bevacizumab based on the FAERS database
    Tang, Linlin
    Ding, Chuanhua
    Li, Hongying
    Yin, Guoqiang
    Zhang, Haixia
    Liu, Wen Shan
    Ji, Yinghui
    Li, Hui
    EXPERT OPINION ON DRUG SAFETY, 2023, : 213 - 220
  • [39] A pharmacovigilance study of adverse event profiles and haemorrhagic safety of bevacizumab based on the FAERS database
    Tang, Linlin
    Ding, Chuanhua
    Li, Hongying
    Yin, Guoqiang
    Zhang, Haixia
    Liu, Wen Shan
    Ji, Yinghui
    Li, Hui
    EXPERT OPINION ON DRUG SAFETY, 2023,
  • [40] Abrocitinib-associated adverse events: a real-world pharmacovigilance study using the FAERS database
    Sun, Yu
    Xu, Tao
    Zhu, Suyan
    Xu, Hongbin
    EXPERT OPINION ON DRUG SAFETY, 2025, 24 (02) : 233 - 239